Cargando…
COVID‐19 hypothesis: Activated protein C for therapy of virus‐induced pathologic thromboinflammation
Seriously ill patients with coronavirus disease 2019 (COVID‐19) at risk for death exhibit elevated cytokine and chemokine levels and D‐dimer, and they often have comorbidities related to vascular dysfunctions. In preclinical studies, activated protein C (APC) provides negative feedback downregulatio...
Autores principales: | Griffin, John H., Lyden, Patrick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292662/ https://www.ncbi.nlm.nih.gov/pubmed/32548551 http://dx.doi.org/10.1002/rth2.12362 |
Ejemplares similares
-
Thromboinflammation in COVID‐19: Can α(2)‐macroglobulin help to control the fire?
por: Seitz, Rainer, et al.
Publicado: (2021) -
Thromboinflammation and the hypercoagulability of COVID‐19
por: Connors, Jean M., et al.
Publicado: (2020) -
Potential Influence of Helminth Molecules on COVID-19 Pathology
por: Siles-Lucas, Mar, et al.
Publicado: (2021) -
Thromboinflammation response to tocilizumab in COVID‐19
por: Gergi, Mansour, et al.
Publicado: (2020) -
Thromboinflammation in COVID-19 acute lung injury
por: Mitchell, William Beau
Publicado: (2020)